Continuing Education Activity
Crotalid envenomations cause a spectrum of disease, with both localized and systemic toxicity, which can result in both prolonged morbidity and rarely mortality. This activity reviews the evaluation and management of patients who suffer crotalid envenomations and highlights the importance of the interprofessional team in the management of these patients.
- Summarize the common components of North American crotalid venom and how these result in clinical toxicity.
- Identify the indications for crotalid antivenom and the common side effects encountered with treatment.
- Review therapies that are and are not recommended in the treatment of crotalid envenomations.
- Describe the importance of collaboration and communication among the interprofessional team to improve outcomes for patients who suffer crotalid envenomations.
Crotalidae, colloquially known as pit vipers, are venomous snakes found throughout the continental United States and Canada. Crotalidae envenomation represents an uncommon but clinically important illness that can result in significant morbidity and rarely mortality. Pitviper venom contains a variety of substances that cause cytotoxicity, myotoxicity, hemotoxicity, and less commonly neurotoxicity. These envenomations can result in a spectrum of disease severity, the extent of which is not always apparent at the initial evaluation. Careful evaluation and monitoring are needed to prevent serious sequelae.
In the US, three types of Crotalidae exist, Copperhead (Agkistrodon contortrix), Cottonmouth (Agkistrodon piscivorus), and multiple species of Rattlesnakes (Crotalus and Sistrurus sp.), which have a wide distribution throughout the United States except for Hawaii and Alaska. Definitive characteristics of these snakes include triangular heads, elliptical eyes, and heat-seeking pits located between their eyes and nostrils. Given that particular species will vary by state and region, knowledge of local geographic distribution can guide proper identification.
Estimates of the number of people who suffer a snakebite each year vary between 5000 and 9000. Males are more likely to suffer envenomations than females, with the vast majority being caucasian. The majority of victims are young adults aged between 20 and 40. There is a smaller peak in those under 12 years of age, leading to the bimodal age distribution of envenomations. Envenomations typically occur in the distal extremities. Lower extremity envenomations are the most common location and usually occur with incidental contact. Upper extremity envenomations, by contrast, are more likely to be due to intentional contact. Envenomations typically occur from late spring to early fall when pit vipers are most active. There is a higher incidence of bites at dawn and dusk, which are peak hunting times for pit vipers. The majority of envenomations are due to rattlesnakes and copperheads, which account for 50 to 55% and 30 to 45% of cases, respectively. Cottonmouth envenomations are relatively rare, contributing to only 5 to 10% of cases. Bites involving larger snakes are associated with more severe envenomations, likely due to their more substantial venom reserves.
Snake venom is a mixture of multiple different compounds, each having different physiologic effects. The specific constitution of an individual snake’s venom will vary by species, geographic location, diet, and even between siblings. In general, the majority of North American crotalid venom contains compounds that are proinflammatory, hemotoxic, cytotoxic, and myotoxic. Venom is rapidly absorbed but slowly eliminated.
Examples of specific compounds identified and their actions:
- Snake venom metalloproteinase (SVMP) has both pro- and anti-coagulation effects. SVMP also contributes to the development of edema, myotoxicity, and inflammation.
- Snake venom serine protease (SVSP) targets the coagulation cascade and causes platelet aggregation.
- Phospholipase A2 has anticoagulant, cytotoxic, and myotoxic effects. It also contributes to the development of edema.
- Disintegrins and C-type lectins modulate platelet aggregation.
Neurotoxins are uncommon among North American Crotalids. However, three particular species: Mojave rattlesnake (C. scutulatus), Timber rattlesnake (C. horridus), Southern Pacific rattlesnakes (C. oreganus helleri) are known to have the Mojave A, or a similar presynaptic neurotoxin.
History and Physical
The first step when evaluating any potential snake envenomation victims is to assess the ABCs: airway, breathing, and circulation. If there is any compromise to these systems, then immediate intervention is warranted before continuing with any further history and exams. Head and neck envenomation is uncommon but can cause significant swelling, which may affect the airway. If envenomation occurring to the head and neck area results in signs of airway compromise, early endotracheal intubation should occur because of the high likelihood of subsequent airway loss. Distal envenomations can precipitate airway compromise by inducing angioedema. Severe envenomations can result in circulatory collapse from massive hemorrhage, third spacing, and hemolysis. If the venom contains a neurotoxin, patients may suffer impairment of respiratory function.
When obtaining a history from a victim of potential envenomation without compromised ABCs, several pieces of information are necessary. The time since the envenomation occurred and the anatomic location of the bite should be asked to allow for appropriate monitoring of local symptom progression. While correct identification of the species involved in the potential envenomation is important, attempting to kill or capture the snake is not advised as it can result in additional bites or victims. A picture, obtained with a cellphone or other portable device, is usually sufficient for identification and can be obtained from a distance safe enough to avoid further envenomation. Again, it should be stressed that preventing additional bites or victims is more important than correct identification of the snake. Both the public and medical professionals require education on this recommendation. Despite these recommendations, it is not unusual for victims to bring a dead snake with them. Health-care providers should understand that handling dead snakes can be dangerous as post-mortem envenomations can occur.
As above the first step in any physical exam, assessment is of the cardiopulmonary system to identify any signs of compromise. Next, examine the envenomation site, which will likely reveal two puncture wounds a few centimeters apart. The leading edge of the erythema/edema should be marked to monitor for progression. Pulse, sensation, and motor function distal to the envenomation also need testing. Remove any restrictive jewelry or clothing, as swelling may progress.A further skin assessment should focus on signs of abnormal bleeding, such as petechiae or ecchymosis. A thorough head to toe exam should be completed to look for other sequelae of envenomation.
The most common localized findings following pit viper envenomation are pain, edema, ecchymosis, and erythema in descending order. Tissue necrosis is possible and more likely to occur with rattlesnake envenomation. Systemic symptoms occur in 15% of patients or less. Systemic manifestations include vomiting, bleeding from distal sites (e.g., gingival bleeding or epistaxis), and/or signs of neurotoxicity (e.g., fasciculations, myokymia, cranial nerve palsies, paresthesias, or respiratory paralysis). Hypotension and/or angioedema, though uncommon, require prompt attention and management.
Providers should assess other symptoms such as chest pain, abdominal pain, headache, etc. These symptoms may be a complication of envenomation such as hemorrhage or thrombosis but may represent a completely separate disease process.
While rattlesnakes are generally recognized as causing more severe envenomations than their Agkistrodon counterparts, species alone does NOT dictate the degree of envenomation. Management should be based on a combination of history, physical, and lab abnormalities, regardless of the species involved.
All potential victims of pit viper envenomation should have a CBC, PTT, PT/INR, and fibrinogen level checked where available. When reviewing the CBC, note any thrombocytopenia or anemia. The other tests attempt to quantify any degree of coagulopathy. If fibrinogen is not available, a D-dimer is an optional substitute. Fibrinogen is more specific for coagulopathies, but the D-dimer is more sensitive. Fibrin splint products have no role in the evaluation of pit viper envenomation. Additional tests are used to evaluate for complications related to envenomations. A comprehensive metabolic profile (CMP) can be useful to assess for hepatic or renal dysfunction. A urinalysis and total creatine kinase (CK) can evaluate for possible rhabdomyolysis. Any further testing should be ordered based on patient complaints, e.g., a patient presenting with chest pain after an envenomation should have an EKG and troponin ordered.
Treatment / Management
As with other soft tissue injuries, all patients with a pit viper envenomation should have their Tetanus updated and receive local wound care with soap/water. Patients should also receive adequate pain control. Despite their efficacy in controlling pain and inflammation, clinicians should avoid NSAIDs due to the potential to worsen a coagulopathy and/or platelet aggregation. Because of this theoretical risk, opioid analgesics are the recommended agents for adequate pain control. Consultation with the regional poison control center can be extremely valuable in assisting with the nuances of a particular case. Each center can provide access to an on-call toxicologist if sub-specialist level advice is warranted. Further treatment recommendations will be based on the severity of envenomation, which broadly falls into four categories.
- Dry: Approximately 20 to 25% of bites result in no envenomation. These patients are largely asymptomatic and have minimal to no localized edema or erythema. There are no signs of coagulopathy on serial lab assessments.
- Mild Envenomation: Approximately 35 to 40% of envenomations result in localized erythema and edema. These symptoms do not involve an entire extremity, and again, there are be no signs of coagulopathy on serial lab assessments.
- Moderate Envenomations: Approximately 15 to 20% of envenomations result in more significant erythema and edema. These envenomations can affect an entire extremity. Systemic symptoms may or may not be present. Minor lab abnormalities may be present as well, but clinically significant bleeding does not occur.
- Severe Envenomations: 5 to 10% of envenomations result in life-threatening coagulopathies with profound localized findings of erythema and edema. Severe systemic signs such as hypotension, angioedema, and/or any signs of neurotoxicity may present. The presence of these symptoms marks a severe envenomation regardless of other findings.
Patients with an apparent dry bite or mild envenomations should have monitoring for 6 to 8 hours. A CBC, coagulation testing, and fibrinogen should be repeated near the end of this observation period. If there are no signs of worsening envenomation, these patients can be safely discharged but should be counseled to return for any signs of bleeding, swelling, or worsening symptoms. All patients with more than a mild envenomation should receive antivenom.
In North American there are two Crotalidae Antivenoms approved for use:
Crotalidae Polyvalent Immune Fab Dosing
Crotalidae Polyvalent Immune Fab is derived from 4 snake species (Western Diamondback, Eastern Diamondback, Mojave rattlesnake, and Cottonmouth ) and immunized into sheep (ovine-derived). The whole immunoglobin is extracted, affinity purified, and cleaved by papain into the terminal Fab fragment of the immunoglobin. This reduces its size by about 1/3 and allows tissue penetration. However, it is cleared renally, and repeat dosing is usually necessary.
The initial dose of antivenom is 4 to 6 vials regardless of age or body mass. A higher dose of 8 to 12 vials merits consideration for patients in shock or with serious bleeding. The initial controlling dose consists of 4-6 vials mixed in 250 mL normal saline (NS) administered over one hour (same number of vials for children). Initiate treatment at a rate of 10 mL/hr observing for adverse effects. If none, then increase every few minutes to achieve complete administration in one hour. Observe patients for local swelling and systemic symptoms. If there are signs of progression, then repeat with 4-6 vials over one hour. After completing this initial dose, both a physical exam and laboratory reassessment must be performed to determine if it achieved initial control. If the exam and/or labs worsen, then a repeat dose of 4 to 6 vials is indicated. This cycle gets repeated until obtaining control. Once initial control has been obtained, patients will require maintenance dosing of 2 vials given at 6, 12, and 18 hours from the time of initial control. If at any point, the envenomation appears to be worsening, the algorithm should be started over with 4 to 6 more vials. All patients requiring antivenom administration should be admitted for continued treatment and monitoring.
Repeat coagulation panel (PT/PTT/INR), fibrinogen, platelets, and hemoglobin on days 2-3 and days 5-7. Recurrent coagulopathy without clinically significant bleeding has been known to occur. Some repeat and follow parameters to normalization. Indications for repeat dosing if coagulopathy occurs between 3 and 7 days after the last dose of Crofab are:
- INR > 3.0
- PTT > 50 seconds
- Platelet Count < 25,000
- Fibrinogen < 50 ug/ml
- Multi-component coagulopathy
Crotalidae Immune F(ab)2 Dosing
Crotalidae Immune F(ab)2 is derived from 2 snakes species (Bothris asper and Crotalus duressis) and immunized in horses (equine-derived). The whole immunoglobin is extracted, purified, and cleaved by pepsin digestion into a fragment with 2 binding sites for venom components - F(ab)2. Despite being derived from horses it is less immunogenic than the original rattlesnake antivenom produced. It is larger in size than Crotalidae Polyvalent Immune Fab and persists in the serum longer with a more sustained duration of the activity, therefore usually not requiring repeat maintenance dosing.
The initial controlling dose consists of 10 vials mixed in 250 mL normal saline (NS) administered over one hour (same number of vials for children). The initial infusion rate for the first 10 minutes should start at 25 to 50 ml/hr, then if no adverse reaction occurs the remaining 250 ml solution can be given over 1 hour.
It is best to evaluate the number fo each of the antivenoms available and not mix loading and maintenance doses between the two products.
In rare severe envenomations, a repeat dose of 10 vials of Anavip may be needed.
Blood products only temporarily correct coagulopathies and thrombocytopenia related to snake envenomation, but this rarely results in long term correction. With this knowledge, blood products such as fresh frozen plasma, platelets, or packed red blood cells should be reserved for patients with medically significant bleeding or patient who have profound coagulopathies despite appropriate antivenom administration.
Aggressive surgical intervention is not indicated, including prophylactic wound excision or fasciotomy. These interventions have not been shown to change outcomes when compared to the administration of antivenom alone and can potentially cause further tissue damage and/or be disfiguring. Compartment syndrome is a rare but serious complication of pit viper envenomation. Diagnosis of compartment syndrome should not rely on “soft” signs but should be through direct compartment pressures or evidence of neurovascular compromise where direct pressures are unobtainable. If compartment syndrome is suspected, administer antivenom as first-line therapy before any fasciotomy or digital dermatome. Antivenom has been shown to reduce compartment pressures significantly.
Several therapies should be avoided as they have no shown to change outcomes and can potentially cause more harm.
- Excision & Suction: Remains common practice among the lay-public. Patients and healthcare providers understand that this does not remove a significant amount of venom and increases local tissue damage.
- Ice: Commonly used to control localized swelling due to musculoskeletal injury, ice is ineffective at controlling swelling due to envenomation. Furthermore, intensive cryotherapy has been shown to worsen outcomes.
- NSAIDs: These agents are usually effective at pain control and edema reduction. However, they theoretically potentiate the effects of venom on platelet aggregation and thus worsen bleeding. Alternative analgesics, such as opiates, should be given instead.
- Electricity: Electricity plays no role in the treatment of envenomations. It increases local tissue damage and does not denature venom.
- Prophylactic antibiotics: Infection appears to be a rare complication of snakebites. As such, prophylactic antibiotics are not indicated and have not been shown to change outcomes. Antibiotics should be used only if signs of secondary infection develop, such as purulence.
- Tourniquets: Tourniquets are a commonly deployed strategy despite evidence that they do not inhibit the absorption of venom effectively and can increase tissue damage. If present on the initial evaluation, any tourniquet should be removed.
- Steroids: There is no evidence of improved outcomes when patients empirically receive steroids. They should be reserved only for hypersensitivity reactions to either venom or antivenom.
It is unlikely that a crotalid envenomation will be mistaken for another disease process given that most patients will present complaining of a snakebite. However, patients do occasionally present reporting concerns for a snakebite even though they are unable to articulate the reason for this suspicion clearly. When evaluating envenomations, the primary decision point is to determine the degree of envenomation as this will guide further treatment. Non-venomous snakes can also cause snakebites; however, these bites will not show any signs of toxicity given the lack of venom.
Localized reactions from other envenomations, such as Hymenoptera, can also cause significant localized pain, erythema, and edema. These could be interpreted as a snake envenomation if a patient did not visualize the cause of their injury. However, unlike snakebites, one would expect only to see a single puncture wound as opposed to two and generally have limited localized edema and erythema.
Patients with skin and soft tissue infections may present with concern for a snakebite. Erythema and edema from secondary infection after an injury may be mistaken for an envenomation. The development of symptoms many hours or several days after an injury is much more suggestive of secondary infection.
Though not impossible, it is unlikely that a patient would suffer a snakebite without actually visualizing a snake.
Toxicity and Side Effect Management
Modern crotalid antivenom Fab, approved by the FDA in 2000, was developed from the serum of sheep inoculated with four species native to the United States: Eastern Diamondback (C. adamanteus), Western Diamondback (C. atrox), Mojave Rattlesnake (C. scutulatus), Cottonmouth (A. piscivorus). The isolated antibodies then undergo proteolytic cleavage into the Fc portion and the Fab portion. The Fab portion, which is less immunogenic, is then isolated and processed into the final product.This modern preparation is responsible for the decreased incidence of immune reactions when compared to the older preparation.
- Hypersensitivity: Type I hypersensitivity is relatively uncommon, with one review showing an incidence of 8%. While rash was the most commonly reported symptom, there are also reports of other symptoms such as urticaria, wheezing, oral swelling, and dyspnea.
- Serum Sickness: Serum sickness has also been reported, with a slightly higher incidence of 13%. Rash/urticaria is, again, the most commonly reported symptom. Other symptoms such as myalgias, arthralgias, fever, anorexia may be present.)
- Pre-treatment does not decrease the incidence of hypersensitivity reactions. Reactions are treated the same as other hypersensitivity reactions, i.e., epinephrine, steroids, antihistamines, and airway management, as indicated. Once reaction symptoms are under control, antivenom therapy should restart at a slower rate. Most patients will be able to complete their antivenom without further incident.
Rattlesnake envenomations resulted in 0 to 4 deaths from 1000 to 1300 exposures per year between 2000 to 2007. Deaths from copperheads are even more rare, with one study showing only 1 death in a 5-year span. Based on the available evidence, most patients receiving prompt evaluation and treatment are expected to survive.
Patients suffering pit viper envenomation can have symptoms that persist for multiple weeks after their initial treatment. Symptom duration will vary by patient and by the severity of envenomation. Generally, patients can expect symptoms to last for at least 2 to 3 weeks. Pain, decreased function of an affected extremity, persistent edema, and lost time from work can last 2 to 4 weeks. Recurrent edema and pain may occur for 1 to 2 months after envenomation.
Up to 5% of patients who are evaluated and treated for envenomations end up readmitted after discharge. Patients are typically readmitted due to worsening symptoms, including edema/erythema or signs of coagulopathy. Recurrent coagulopathy with bleeding affects less than 1% of victims. Even fewer victims, about 0.5%, develop medically significant late bleeding. These patients are much more likely to have been the victim of rattlesnake envenomation.
Myonecrosis/Rhabdomyolysis: Rhabdomyolysis may develop as a result of venom-induced myonecrosis. A patient’s total CK and renal function require monitoring if rhabdomyolysis is suspected. Treatment does not differ from other causes of rhabdomyolysis.
Compartment syndrome: As addressed in the previous sections, compartment syndrome is a rare but serious complication of pit viper envenomation. Any patients with suspected compartment syndrome should receive antivenom prior to any surgical fasciotomy or digital dermatomy. Serial compartment pressures can be obtained to monitor progression or improvement.
Bleeding: Though clinically significant bleeding is rare, bleeding may occur either at the site of envenomation or at distal sites; this is due to the venom’s effect on both the coagulation pathways and platelet aggregation. Signs of distal bleeding commonly include gingival bleeding, epistaxis, and/or petechiae. However, bleeding can also present as headache or abdominal pain in the rare instance of intracranial or intraabdominal/retroperitoneal bleeding, respectively.
Anemia/Thrombocytopenia: Antivenom is the first-line treatment for any hematologic abnormalities. Transfusion should only be a consideration after administering antivenom.
Angioedema/hives: As discussed in the previous sections, hypersensitivity reactions are uncommon. If present, treatment includes steroids, epinephrine, and antihistamines in addition to antivenom. Airway management may be necessary if significant angioedema is present.
Deterrence and Patient Education
- Do not actively engage pit vipers. A significant number of cases are preventable if people give pit vipers space to escape and are do not handle them.
- Maintain situational awareness in settings where pit vipers live and hunt. It is possible to encounter pit vipers in many parts of the US. However, they are less common in densely populated areas. If planning a trip into sparsely populated areas, it is prudent to review local dangerous flora and fauna.
- Medical attention should be sought immediately for any snakebite as their evaluation will be inadequate outside of a medical setting. Lack of immediate symptoms does not guarantee a dry bite, and serious sequelae may take several hours to develop.
- As stated before, no attempt to kill or capture the snake should occur. If it can be safely managed, a picture is usually sufficient for identification.
- Many contraindicated treatments persist as common practice among the lay-public despite convincing evidence that they, at best, do not work and are more likely to cause additional harm. Patients should be counseled not to perform any contraindicated treatments such as cutting, suction, electricity, ice, or tourniquets.
Enhancing Healthcare Team Outcomes
The evaluation and management of patients with a potential crotalid envenomation require an interprofessional team of at the very least nursing, emergency physician, and regional poison center. Depending on the severity of envenomation, this team may also include a hospitalist, intensivist, surgeon, and/or other medical or surgical subspecialties depending on the complications of each case. Nursing staff plays a vital role in communicating changes in the patients’ status with the treating physician. Patients suffering from envenomation require frequent reassessments and vital sign checks to monitor for disease progression. A pharmacist with board certification in applied toxicology can provide direction on antivenom dosing, preparation, and administration. They will also be the first to note any potential side effects from antivenom administration. Prompt communication with the regional poison control center, especially for patients with signs of significant envenomation, is crucial for optimal management. Proper communication between all members of the interprofessional treatment team is vital to ensure patients receive the best evidence-based management and obtain the best outcome possible. [Level 5]